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Variants in Pharmacokinetic Transporters and
Glycemic Response to Metformin: A MetGen
Meta-Analysis
T Dujic1,2, K Zhou2, SW Yee3, N van Leeuwen4, CE de Keyser5,6, M Javorsky7,8, S Goswami3,
L Zaharenko9, MM Hougaard Christensen10, M Out11,12, R Tavendale2, M Kubo13, MM Hedderson14,
AA van der Heijden15, L Klimcˇakova16, V Pirags9, A Kooy11,12, K Brøsen17, J Klovins9, S Semiz1,18,
I Tkacˇ7,8, BH Stricker5,6,19, CNA Palmer2, LM ’t Hart4,20,21, KM Giacomini3,22 and ER Pearson2
Therapeutic response to metformin, a first-line drug for type 2 diabetes (T2D), is highly variable, in part likely due to genetic
factors. To date, metformin pharmacogenetic studies havemainly focused on the impact of variants in metformin trans-
porter genes, with inconsistent results. To clarify the significance of these variants in glycemic response to metformin in
T2D, we performed a large-scalemeta-analysis across the cohorts of the Metformin Genetics Consortium (MetGen). Nine
candidate polymorphisms in five transporter genes (organic cation transporter [OCT]1, OCT2, multidrug and toxin extrusion
transporter [MATE]1, MATE2-K, and OCTN1) were analyzed in up to 7,968 individuals. None of the variants showed a signifi-
cant effect onmetformin response in the primary analysis, or in the exploratory secondary analyses, when patients were
stratified according to possible confounding genotypes or prescribed a daily dose of metformin. Our results suggest that
candidate transporter gene variants have little contribution to variability in glycemic response to metformin in T2D.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 Published studies on the impact of the polymorphisms in
organic cation transporter genes on metformin response have
been inconsistent and mostly hindered by small sample size.
WHAT QUESTION DID THIS STUDY ADDRESS?
 This study explored whether variations in metformin trans-
porter genes affect glycemic response to metformin through a
large-scale meta-analysis.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 Nine candidate variants in membrane transporter genes
showed no significant effect on metformin response, assessed as
HbA1c reduction, in patients with T2D.
HOW THIS MIGHT CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE
 Candidate variants in transporter genes, despite their role in
metformin pharmacokinetics, showed no relevant contribution
to variability in metformin efficacy and might not be useful as
predictors for individualized treatment with metformin.
Metformin is the first-line pharmacological therapy for type 2
diabetes (T2D) and the most widely prescribed antidiabetic drug.
The glycemic response to metformin is, however, highly variable.
In patients receiving metformin as an initial treatment for T2D,
less than two-thirds achieve acceptable glycemic control or a
target HbA1c <7% (53 mmol/mol).
1,2 Genetic factors play an
important role in the variable glycemic response to metformin,
with up to 34% of variance in HbA1c reduction explained by
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common genetic variants, each conferring a small to moderate
impact.3 As a result, a large sample size is required for pharmaco-
genetic studies aiming to discover these common metformin
response variants.
Previously published studies of metformin pharmacogenetics
have mostly focused on the candidate genes involved in drug
pharmacokinetics, with the expectation that these might have a
large clinical effect. For example, polymorphisms in the trans-
porters, organic anion-transporting polypeptide 1B1 and breast
cancer resistance protein, have been associated with large effect
sizes with the pharmacokinetics and pharmacodynamics of sever-
al drugs, including statins.4 Metformin is not metabolized and is
excreted unchanged by the kidneys. Its primary mode of action
seems to be an increase of hepatic insulin sensitivity through inhi-
bition of gluconeogenesis,5 although there is increasing recogni-
tion of its role in the gut.6 As metformin is an organic cation at
physiologic pH, cation-selective carrier proteins mediate its trans-
port across cell membranes in the intestine, liver, and kidneys.
Organic cation transporter 1 (OCT1; encoded by SLC22A1) is
expressed on the sinusoidal membrane of hepatocytes and is the
main transporter of metformin into the liver.7 Organic cation
transporter 2 (OCT2; encoded by SLC22A2) is expressed
primarily at the basolateral membrane in the kidney tubular cells
and facilitates the uptake of metformin from the blood into the
kidneys.8 The multidrug and toxin extrusion transporter 1
(MATE1; encoded by SLC47A1) and MATE2-K (encoded by
SLC47A2), are H1/drug antiporters located in the apical mem-
brane of the renal tubular cells, and facilitate metformin excre-
tion from tubular cells into urine.9–11 A recent study showed
that metformin is also a substrate of carnitine/cation transporter
1 (OCTN1; encoded by SLC22A4).12 OCTN1 is highly
expressed at the apical membranes in renal proximal tubules and
could also contribute to metformin elimination.13,14 To date, sev-
eral polymorphisms in these transporter genes have been associat-
ed with the pharmacokinetics and pharmacodynamics of
metformin in healthy volunteers15–18 and with metformin
response in T2D.18–25 In addition, a few studies have reported
gene-gene interactions between polymorphisms in transporter
genes.18,22,26 However, the results of these studies have been
inconsistent and the impact of the established pharmacokinetic
variants on metformin clinical response in T2D is uncertain.27
Apart from the different measures of glycemic response used in
these studies, the small sample size and reporting bias is another
potential explanation for the observed inconsistency.
To clarify the role of genetic variants in these transporters on
metformin clinical response, we performed a large-scale meta-
analysis of the impact of known candidate variants on metformin
efficacy in T2D, across the cohorts of recently established Metfor-
min Genetics Consortium (MetGen). This resource now has in
excess of 10,000 individuals in whom metformin response can be
defined, and offers a unique opportunity for a highly powered
pharmacogenetic meta-analysis of glycemic response to metformin.
RESULTS
We studied the effect of nine candidate variants in transporter genes
OCT1,15,16,19,20,23,28 OCT2,17,23,25,29,30 MATE1,18,21,23,25,28,31
MATE2-K,18,24 and OCTN114,28 (Table 1) on metformin glyce-
mic response in 7,968 MetGen participants of European ancestry.
Of these, the definition of metformin response could be aligned for
a meta-analysis in 7,656 participants, of whom 5,836 were initiated
Table 1 Single-nucleotide polymorphisms explored in the meta-analysis
Gene dbSNP ID
Nucleotide
change
Amino acid
change MAFa Reference
OCT1 (SLC22A1) rs12208357 c.181C>T R61C 0.06 Shu et al., 200715; Shu et al., 200816;
Tzvetkov et al., 200928; Zhou et al., 200919;
Christensen et al., 201123
rs72552763 c.1260GAT>del M420del 0.1915,45 Shu et al., 200715; Shu et al., 200816;
Tzvetkov et al., 200928; Zhou et al., 200919;
Christensen et al., 201123
rs622342 Intron A>C 0.38 Becker et al., 200920; Christensen et al., 201123
OCT2 (SLC22A2) rs316019 c.808G>T A270S 0.11 Song et al., 200829; Wang et al., 200830;
Chen et al., 200917; Christensen et al., 201123;
Tkacˇ et al., 201325
MATE1 (SLC47A1) rs2289669 Intron G>A 0.42 Becker et al., 200921; Tzvetkov et al., 200928;
Jablonski et al., 201031; Christensen et al., 201123;
Tkacˇ et al., 201325
rs2252281 g.-66T>C 0.41 Stocker et al., 201318
MATE2-K (SLC47A2) rs12943590 g.-130G>A 0.27 Choi et al., 201124; Stocker et al., 201318
OCTN1 (SLC22A4) rs272893 c.917C>T T306I 0.41 Yoon et al., 201314
rs1050152 c.1507C>T L503F 0.39 Tzvetkov et al., 200928
Minor alleles are shown in bold.
dbSNP, single nucleotide polymorphism database; ID, identification; MAF, minor allele frequency; MATE1, multidrug and toxin extrusion transporter; OCT1, organic cation
transporter.
aMinor allele frequencies from 1000 Genome Project Phase 3 EUR population (www.ncbi.nlm.nih.gov/projects/SNP).
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on metformin monotherapy and 1,820 were initiated on metformin
as add-on treatment for sulfonylureas (dual therapy; Table 2). Forest
plots for the meta-analyses of the individual variants in the mono-
therapy group are presented in Figure 1. There was no significant
heterogeneity between the studies for any polymorphism. None of
the variants was significantly associated with glycemic response to
metformin (Figure 1). Similarly, when patients on monotherapy
and dual therapy were analyzed together, no single-nucleotide
polymorphism (SNP) showed significant association with HbA1c
reduction (Supplementary Table S1 online). The results from
the HOME and SDDS studies, two MetGen cohorts in which met-
formin was added to insulin therapy, did not show significant
impact on metformin response assessed as HbA1c reduction
(Supplementary Table S2 online).
As the transport of metformin could depend on its concentra-
tion, we next explored possible gene by dose interactions, using a
dose as a proxy of metformin concentration. In the meta-analysis
of SNP 3 dose interaction effects, none of the interactions
showed significant effect in the monotherapy group (Table 3) or
the total group when patients on dual therapy were added to the
analysis (Supplementary Table S3a online). Likewise, no signifi-
cant associations were found in the separate meta-analyses of the
effects of variants on metformin response in individuals treated
with low (1,000 mg) or high daily doses of metformin (>1,000 mg;
Table 4 and Supplementary Table S3b online).
We next explored the potential interactions between these trans-
porters that might affect metformin response. The interactions
were tested by examining the impact of one SNP in two separate
subgroups of participants, homozygotes for the reference, and vari-
ant allele of a potential confounding SNP. Tables 5a and 5b show
the results from meta-analyses of participants on monotherapy for
transporters in the liver and kidneys, respectively. Supplementary
Tables S4a and S4b online show the meta-analyses results for all
participants, including both monotherapy and dual therapy. These
exploratory subgroup analyses revealed no significant interactions
between the SNPs that affect metformin glycemic response.
In the supplemental locus-wise meta-analysis of the association
of all common SNPs in transporter gene regions with metformin
glycemic response, none of the variants showed significant
signal after correction for multiple testing (P > 1.6 3 1024;
Supplementary Figure S1).
DISCUSSION
Despite the established role of cation-selective transporters in
metformin pharmacokinetics, polymorphisms in these transport-
ers showed no significant impact on glycemic response to metfor-
min in this large study of patients with T2D. This meta-analysis
had 80% power to detect an allelic effect of HbA1c reduction
>0.14% (1.5 mmol/mol) for any of the candidate SNPs at the
nominal significance level of a 5 0.005. Thus, none of the SNPs
reported as being associated with metformin response in previous
literature is likely to have an allelic impact on HbA1c reduction
of >0.14%. Furthermore, it is unlikely that other SNPs, such as
cis-regulatory variants, in these genes could have a significant
impact on metformin glycemic response, as shown by a locus-
wise meta-analysis of all common SNPs within genes’ proximity
in 6,964 patients.
Our findings contrast to most of those previously reported in
healthy subjects,15–18 although it is in keeping with a recent study
showing no impact of the OCT1 genotype on the glucose pro-
duction in fasting healthy subjects.32 This may reflect the fact
that our study was conducted on patients with T2D and, as such,
we were able to assess HbA1c reduction rather than other surro-
gates of metformin response. Some18,20,21,23–25 but not all19 pre-
vious studies have reported an association of a variant altering
metformin transport and glycemic response to metformin in
Table 2 Characteristics of cohort participants included in the meta-analysis
Characteristic DCS GoDARTS Kosice PMT1-EU PMT2-EU Riga Rotterdam Sarajevo
No. of participants 1,380 3,170 148 125 2,358 64 323 87
Age, years 62.16 10.6 61.96 11.1 57.56 10.4 57.26 12.9 66.26 9.8 59.76 10.7 69.76 10.6 58.26 9.0
Sex, male, % 757 (55) 1,813 (57) 72 (49) 61 (49) 1,283 (54) 19 (30) 147 (46) 37 (43)
BMI, kg/m2 30.96 5.2 31.76 5.9 31.56 4.6 37.76 9.1 32.36 6.8 34.46 5.2 29.56 4.7 31.26 4.3
Pretreatment
HbA1c, %
7.3 6 1.3 8.96 1.4 7.66 1.1 7.8 6 1.3 7.86 1.5 7.16 1.1 7.86 1.3 7.86 1.4
On-treatment HbA1c 6.6 6 0.8 7.26 1.1 7.06 0.8 6.7 6 0.8 6.56 0.8 6.46 0.5 6.76 0.7 6.76 0.7
Creatinine
clearance, ml/mina
1056 38 93.26 35.4 1046 36 80.26 20.1 100.06 38.1 122.46 44.5 85.26 32.6 109.56 30.4
Metformin daily
dose, mg
1,0896 597 1,3216 515 1,4006 540 9136 326 9326 490 1,7046 579 8006 480 1,2006 608
Adherence – 82.46 16.2 – >80b 88.96 20.4 – 796 34 –
Metformin
monotherapy, %
85 69 100 100 75 100 88 100
BMI, body mass index.
aCreatinine clearance was estimated using the Cockcroft-Gault formula, except for the PMT1-EU study in which the MDRD formula was used. bPatients needed to have
80% adherence to be included in the study.
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patients with T2D. These studies have varied in size but have
generally been small, and have varied in their definition of glyce-
mic response to metformin and analytical approaches. In this
MetGen meta-analysis, we included all studies that have previous-
ly explored associations between transporter variants and glyce-
mic response to metformin in patients with T2D of European
ancestry with both positive and negative findings,18–25 and also
other cohorts for which results have not been published. In this
way, we have reduced the chance of reporting bias and maximized
the power. In addition, we have reduced heterogeneity by align-
ing metformin response definitions, models, and covariates for all
studies included in the meta-analysis. Our results suggest that
metformin transporters do not have a significant role in how
patients with T2D respond to metformin therapy.
Transporters exhibit asymmetry in their kinetic properties;
thus, for facilitated transporters that are bidirectional, the direc-
tion of the transport will depend on the substrate concentra-
tion.33,34 Systemic plasma levels of metformin are dependent on
dose; therefore, in our secondary analyses, we analyzed dose 3
SNP interactions and assessed the effect of the studied variants
separately in individuals prescribed low (1,000 mg) or high
(>1,000 mg) doses of the drug. We did not find significant
impact of the analyzed interactions on metformin glycemic
response, and, accordingly, significant association between any
variant and response in the dose-stratified analysis. However, we
used the prescribed dose as a proxy of metformin concentration.
There were differences in the characteristics of patients between
the cohorts, and, for instance, older age and lower estimated glo-
merular filtration rate in the Rotterdam cohort could result in
higher metformin serum levels, despite being prescribed lower
doses. In addition, data on drug adherence were available only in
four studies, although all studies were adjusted for creatinine
clearance and other known clinical covariates, which could influ-
ence metformin response.
Studies of small cohorts have previously reported gene-gene
interactions affecting glycemic response to metformin.18,22 Here,
we explored whether such interactions could explain the lack of
association between metformin response and transporter variants.
The exploratory analyses of SNP 3 SNP interactions, assessed as
the impact of studied polymorphisms on metformin response in
the subgroups of patients homozygous for possibly confounding
SNPs, did not show any significant effects. However, these sub-
group analyses had substantially less power to detect moderate
effects due to the smaller sample sizes, especially for the rarer
SNPs. Larger studies would be needed to detect these effects
and to explore possible but more complex multiple gene-gene
interactions.
This is the largest metformin pharmacogenetic study reported
to date, despite a few limitations due to the need to align cohorts.
Our finding that there is no significant role for metformin trans-
porter variants in mediating glycemic response to metformin
challenges our understanding of metformin action in patients
with T2D chronically treated with metformin. For example,
there is increasing recognition that metformin works presystemi-
cally in the gut, via a number of mechanisms, to improve glyce-
mia.6,35–37 Indeed, a recent delayed release metformin achieves
Figure 1 Effects of candidate variants in transporter genes on metformin
glycemic response assessed as HbA1c reduction in patients on metformin
monotherapy. Beta values obtained from individual studies are presented
with 95% confidence interval (CI); arrowheads indicate the CI exceeding the
limits of the graph. Overall betas are presented as black diamonds. The
organic cation transporter 1 (OCT1) reduced-function (RF) alleles denote
combined genotype for R61C and M420del – number of RF alleles. MATE1,
multidrug and toxin extrusion transporter 1. [Color figure can be viewed at
wileyonlinelibrary.com]
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low systemic metformin concentrations but is effective at lower-
ing blood glucose in patients with T2D.38 It is also possible that
the influence of the analyzed transporter gene variants is less
prominent clinically than expected due to the redundancy of
transporters in vivo.27 If one or more transporters have reduced
function, other transporters may take over their roles and medi-
ate metformin uptake or efflux from the organs. In addition,
there might be more membrane transporters of metformin yet to
be identified that could have a role in its absorption, distribution,
and elimination. In the current study, we focused on the candi-
date variants in the membrane transporter genes that have been
associated previously with metformin pharmacokinetics or
response. However, in addition to liver and kidney transporters,
transporters in the intestine may play a significant role in metfor-
min levels. Recent studies have suggested that other transporters,
which were not the subject of this study, play an important role
in metformin absorption,34,39–41 and there still may be unidenti-
fied cation transporters in the intestine involved in metformin
absorption, which could also affect metformin response. It should
also be noted that variants in transporters in various tissues may
play opposing roles. For example, OCT1 could mediate basolat-
eral flux of metformin from enterocytes to the portal circula-
tion7,42 and across the sinusoidal membrane of hepatocytes.7
Thus, a reduced function OCT1 genetic variant may result in
increased concentrations in enterocytes and decreased concentra-
tions in hepatocytes.
Table 3 Meta-analysis results of single-nucleotide polymorphism3 dose interaction effects in participants on metformin
monotherapy
SNP
Effect
allele
No. of
studies
No. of
patients
Continuous dose Dichotomous dose
Beta SE P value I2 P(Q) Beta SE P value I2 P(Q)
OCT1 R61C T 5 4,376 0.005 0.019 0.816 0.0 0.965 -0.005 0.078 0.946 0.0 0.720
OCT1 M420del del 4 4,297 0.006 0.014 0.669 0.0 0.502 0.043 0.089 0.631 61.8 0.049
OCT1 RF allelesa 4 3,986 0.001 0.012 0.923 0.0 0.659 0.041 0.049 0.394 44.0 0.148
OCT1 rs622342 C 5 5,273 0.028 0.010 0.006 39.8 0.156 0.092 0.037 0.014 0.0 0.413
OCT2 A270S T 6 5,002 0.008 0.017 0.647 30.8 0.205 -0.003 0.056 0.952 23.0 0.261
MATE1 rs2289669 A 6 4,980 0.014 0.008 0.094 0.2 0.415 0.081 0.036 0.024 0.0 0.485
MATE1 rs2252281 C 4 2,528 0.004 0.015 0.791 0.0 0.505 0.059 0.043 0.177 0.0 0.484
MATE2 rs12943590 A 6 4,273 -0.008 0.011 0.467 0.0 0.663 0.007 0.044 0.875 0.0 0.827
OCTN1 T306I T 6 4,647 -0.005 0.010 0.624 0.0 0.466 -0.006 0.037 0.879 0.0 0.875
OCTN1 L503F T 4 4,202 0.025 0.016 0.110 60.4 0.056 0.120 0.085 0.161 76.0 0.006
I2, heterogeneity index; MATE, multidrug and toxin extrusion transporter; OCT1, organic cation transporter 1; P(Q), P value for Cochrane’s Q statistic; RF, reduced function;
SNP, single-nucleotide polymorphism.
aCombined genotype for R61C and M420del – number of reduced-function alleles. A positive beta is a greater glycemic response to metformin associated with the effect allele.
Table 4 Meta-analysis results for the effects of candidate variants in transporter genes on metformin glycemic response in partici-
pants on metformin monotherapy, stratified by metformin dose
SNP
Effect
allele
No. of
studies
Dose 1,000 mg Dose >1,000 mg
No. of patients Beta SE P value I2 P(Q) No. of patients Beta SE P value I2 P(Q)
OCT1 R61C T 5 3,015 0.019 0.038 0.619 0.0 0.855 1,361 0.000 0.000 1.000 0.0 0.719
OCT1 M420del del 4 2,903 -0.001 0.050 0.987 55.6 0.080 1,394 0.013 0.040 0.747 44.9 0.142
OCT1 RF allelesa 4 2,690 0.006 0.025 0.812 0.2 0.391 1,296 0.032 0.039 0.412 26.1 0.255
OCT1 rs622342 C 5 3,571 -0.004 0.019 0.837 0.0 0.523 1,702 0.055 0.030 0.064 0.0 0.679
OCT2 A270S T 6 3,388 0.013 0.029 0.659 0.0 0.749 1,614 0.062 0.082 0.453 50.9 0.070
MATE1 rs2289669 A 6 3,428 -0.014 0.018 0.452 38.1 0.152 1,552 0.060 0.030 0.046 20.0 0.282
MATE1 rs2252281 C 4 1,629 0.004 0.026 0.877 0.0 0.750 899 -0.006 0.031 0.843 32.2 0.219
MATE2 rs12943590 A 6 3,009 -0.012 0.023 0.592 0.0 0.799 1,264 -0.070 0.088 0.431 93.1 0.000
OCTN1 T306I T 6 3,116 0.017 0.020 0.401 0.0 0.728 1,531 0.038 0.033 0.251 0.0 0.971
OCTN1 L503F T 4 2,889 -0.044 0.020 0.028 35.8 0.197 1,313 -0.029 0.036 0.434 48.4 0.121
I2, heterogeneity index; MATE, multidrug and toxin extrusion transporter; OCT1, organic cation transporter 1; P(Q), P value for Cochrane’s Q statistic; RF, reduced function;
SNP, single-nucleotide polymorphism.
aCombined genotype for R61C and M420del – number of reduced-function alleles. A positive beta is a greater glycemic response to metformin associated with the effect allele.
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Although the current study demonstrates that genetic variants
in transporters that play a role in metformin pharmacokinetics
have no significant effect on metformin glycemic response in
large cohorts of patients with diabetes, there are some limitations
to our study. First, despite the large sample size used in the cur-
rent study, we did not have the statistical power to detect an alle-
lic effect size for HbA1c reduction smaller than 0.06–0.14%
(0.7–1.5 mmol/mol, depending on SNP frequency), however,
these small effect sizes may be unlikely to have any clinical impor-
tance. Second, the meta-analysis included population-based
observational studies, which could be confounded by a number
of factors, such as patient adherence or frequency of HbA1c meas-
urements in the cohort. However, in four cohorts, including two
largest cohorts, GoDARTS and PMT2-EU, adherence could be
calculated from the drug dispensing records, and was added as a
covariate in the model. Likewise, although we could not
completely harmonize the definition of on-treatment HbA1c due
to different frequency of HbA1c measurements available in the
cohorts, four studies, including two of the largest studies, used
minimal HbA1c achieved within 18 months as outcome. Third,
concomitant medications, which affect metformin transport, are
well established to cause changes in its pharmacokinetics,43 and
may obscure effects of genetic variants on metformin response.
Information on prescription and over-the-counter drugs that
affect metformin pharmacokinetics, such as cimetidine, were not
gathered in the current study. In addition, several previous studies
have shown effects of polymorphisms in transporters on
metformin response in multi-ethnic cohorts, including many
individuals from non-European ancestries.18,24 Genetic variants
may have different effect sizes on drug response in individuals
from different ethnic backgrounds. Further studies are needed to
test the effects of these variants on metformin response in indi-
viduals from non-European backgrounds. Finally, recent studies
suggest that genetic variants in transcription factors that affect
expression of several metformin transporters may have larger
effect sizes on metformin response than genetic variants in the
individual transporters themselves,44 underscoring the need to
understand not only the mechanisms of metformin transport in
various tissues, but the proteins that modulate their activity and
expression.
In conclusion, in our large meta-analysis, including almost
8,000 individuals across 10 international cohorts of the MetGen
Consortium, variants in metformin transporter genes have shown
no relevant contribution to variability in metformin response
in patients with T2D, although we cannot rule out gene-
concentration or more complex multiple gene-gene interactions
that may be required to account for transporter redundancy. As
has been recognized now for a number of years in disease and
complex trait genetics, this study shows the importance of large
sample sizes, usually only available to international consortia, for
robust pharmacogenetic studies. Future even larger consortia
efforts are required to corroborate these findings and to unravel
genetic variations that could be used as better predictors for
personalized metformin therapy.
Table 5a Meta-analysis results for the effects of individual single-nucleotide polymorphisms in the subgroups of patients homozy-
gous for the wild-type or variant allele of possible confounding single-nucleotide polymorphisms – interactions between metformin
liver transporters – monotherapy group
Subgroup SNP
Effect
allele
No. of
studies
No. of
patients Beta SE P value I2 P(Q)
0 OCT1 RF allelesa MATE1 rs2289669 A 5 1,736 0.004 0.029 0.879 0.0 0.468
MATE1 rs2252281 C 4 891 0.028 0.045 0.542 0.0 0.976
2 OCT1 RF alleles MATE1 rs2289669 A 5 179 -0.095 0.108 0.380 80.6 0.000
MATE1 rs2252281 C 4 102 0.167 0.136 0.221 66.5 0.030
OCT1 rs622342 wt/wt MATE1 rs2289669 A 6 1,899 0.007 0.026 0.789 0.0 0.429
MATE1 rs2252281 C 4 997 0.046 0.036 0.204 0.0 0.799
OCT1 rs622342 v/v MATE1 rs2289669 A 6 596 0.084 0.063 0.178 61.7 0.023
MATE1 rs2252281 C 4 329 0.060 0.051 0.243 35.5 0.200
MATE1 rs2289669 wt/wt OCT1 RF alleles 5 1,179 0.025 0.036 0.494 31.6 0.211
OCT1 rs622342 C 6 1,608 0.035 0.049 0.477 53.2 0.058
MATE1 rs2289669 v/v OCT1 RF alleles 5 292 -0.008 0.080 0.921 0.0 0.779
OCT1 rs622342 C 6 527 0.024 0.053 0.653 0.0 0.505
MATE1 rs2252281 wt/wt OCT1 RF alleles 4 606 0.064 0.052 0.213 0.0 0.837
OCT1 rs622342 C 4 956 0.040 0.035 0.250 0.0 0.870
MATE1 rs2252281 v/v OCT1 RF alleles 4 256 -0.005 0.092 0.957 49.1 0.117
OCT1 rs622342 C 4 373 0.019 0.054 0.734 0.0 0.575
I2, heterogeneity index; MATE, multidrug and toxin extrusion transporter; OCT1, organic cation transporter 1; P(Q), P value for Cochrane’s Q statistic; RF, reduced function;
SNP, single-nucleotide polymorphism; v/v, homozygous variant allele carriers; wt/wt, homozygous wild-type allele carriers.
aCombined genotype for R61C and M420del - number of RF alleles. A positive beta is a greater glycemic response to metformin associated with the effect allele.
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Table 5b Meta-analysis results for the effects of individual single-nucleotide polymorphisms in the subgroups of patients homozy-
gous for the wild-type or variant allele of possible confounding single-nucleotide polymorphisms - interactions between metformin kid-
ney transporters - monotherapy group
Subgroup SNP
Effect
allele
No. of
studies
No. of
patients Beta SE P value I2 P(Q)
OCT2 A270S wt/wt MATE1 rs2289669 A 7 3,869 0.008 0.018 0.673 41.9 0.112
MATE1 rs2252281 C 5 1,835 -0.008 0.027 0.756 0.0 0.964
MATE2 rs12943590 A 7 3,176 -0.011 0.023 0.642 0.0 0.481
OCTN1 T306I T 7 3,642 0.030 0.019 0.118 0.0 0.660
OCTN1 L503F T 5 3,437 -0.040 0.019 0.034 0.0 0.720
OCT2 A270S v/v MATE1 rs2289669 A 3 59 0.045 0.210 0.831 0.0 0.950
MATE1 rs2252281 C 2 35 0.575 0.175 0.001 31.8 0.226
MATE2 rs12943590 A 3 48 0.170 0.337 0.615 0.0 0.557
OCTN1 T306I T 3 51 0.164 0.212 0.440 34.6 0.217
OCTN1 L503F T 3 50 -0.017 0.206 0.934 20.3 0.285
MATE1 rs2289669 wt/wt OCT2 A270S T 7 1,598 0.021 0.042 0.613 0.0 0.568
MATE2 rs12943590 A 7 1,288 -0.066 0.071 0.347 58.9 0.024
OCTN1 T306I T 7 1,412 0.044 0.054 0.418 63.4 0.012
OCTN1 L503F T 5 1,328 -0.069 0.029 0.015 0.0 0.884
MATE1 rs2289669 v/v OCT2 A270S T 6 495 -0.066 0.146 0.655 65.0 0.014
MATE2 rs12943590 A 7 363 0.065 0.052 0.215 0.0 0.529
OCTN1 T306I T 7 410 0.138 0.053 0.009 6.4 0.379
OCTN1 L503F T 5 365 -0.156 0.055 0.004 0.0 0.612
MATE1 rs2252281 wt/wt OCT2 A270S T 5 862 -0.014 0.056 0.802 0.0 0.942
MATE2 rs12943590 A 5 720 0.006 0.046 0.902 9.2 0.354
OCTN1 T306I T 5 726 -0.037 0.042 0.382 47.5 0.107
OCTN1 L503F T 4 662 -0.017 0.046 0.711 19.9 0.290
MATE1 rs2252281 v/v OCT2 A270S T 4 329 0.129 0.076 0.087 0.0 0.592
MATE2 rs12943590 A 5 276 -0.042 0.061 0.494 0.0 0.829
OCTN1 T306I T 5 283 0.013 0.067 0.853 22.1 0.274
OCTN1 L503F T 4 262 -0.011 0.074 0.884 0.0 0.650
MATE2 rs12943590 wt/wt OCT2 A270S T 7 1,964 0.001 0.036 0.978 22.4 0.259
MATE1 rs2289669 A 7 1,980 -0.010 0.023 0.673 0.0 0.454
MATE1 rs2252281 C 5 1,014 0.051 0.034 0.138 0.0 0.661
OCTN1 T306I T 7 1,828 0.043 0.026 0.095 39.7 0.127
OCTN1 L503F T 5 1,636 -0.050 0.027 0.062 26.4 0.246
MATE2 rs12943590 v/v OCT2 A270S T 7 298 -0.017 0.088 0.849 0.0 0.830
MATE1 rs2289669 A 7 300 0.183 0.115 0.112 51.3 0.055
MATE1 rs2252281 C 5 139 0.089 0.097 0.357 0.0 0.534
OCTN1 T306I T 7 279 -0.071 0.056 0.203 0.0 0.744
OCTN1 L503F T 5 241 0.080 0.058 0.168 0.0 0.455
Table 5b Continued on next page
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METHODS
Studies
The MetGen Consortium consists of research groups from Europe and
the United States with available data for studies of metformin pharma-
cogenetics from population observational studies and clinical trials. The
10 MetGen cohorts with available data for the study of metformin
transporter gene variants are presented in Supplementary Table S5
online. The studies were approved by relevant institutional review
boards, and all participants gave written informed consent.
Single-nucleotide polymorphism selection and genotyping
Nine SNPs in five transporter genes, reported to be associated with met-
formin response or pharmacokinetics in previous studies, were included
in the meta-analysis (Table 1). The numbers of available SNPs, genotyp-
ing methods, and the minor allele frequencies in each cohort are provid-
ed in Supplementary Table S6 online. All SNPs were in line with
Hardy-Weinberg equilibrium (P > 0.01). The variants were first ana-
lyzed individually for association with metformin response. The
reduced-function OCT1 polymorphisms, R61C and M420del, were ana-
lyzed individually, and also together as a combined genotype, according
to the number of haplotypes carrying reduced-function alleles: 0, 1, or 2,
in line with previous studies in patients of European ancestry.23,45,46
Assessment of metformin response
Metformin response was defined as a reduction in HbA1c during treat-
ment with metformin: pretreatment minus on-treatment HbA1c. As
such, a positive b in the regression models indicates an association of the
effect allele with greater glycemic response to metformin. Inclusion crite-
ria for all participants included in the meta-analysis were continuous
treatment with metformin for at least 3 months, pretreatment HbA1c
measured within 6 months prior to metformin therapy and <14%, mea-
surement of on-treatment HbA1c within 18 months of metformin com-
mencement, and no treatment with other glucose-lowering agents except
stable sulfonylurea treatment before and during metformin therapy.
Hence, two cohorts from randomized controlled trials, HOME and
SDDS studies, in which metformin was added to insulin therapy, were
not included in the meta-analysis, and the results are shown separately.
On-treatment HbA1c was defined as minimal HbA1c measured within
18 months of metformin commencement in the GoDARTS, PMT2-
EU, Riga, and Rotterdam studies, as HbA1c measured after 6 months
(Kosice and Sarajevo studies) or 12 months (DCS study) of metformin
treatment, and as HbA1c measured within the first 3–9 months of met-
formin therapy in the PMT1-EU study.
Statistical analysis
In each cohort, the effects of individual SNPs on metformin response
were assessed in additive genetic model using linear regression with
reduction of HbA1c as outcome (primary analysis). The pretreatment
HbA1c, metformin daily dose, adherence, creatinine clearance, baseline
gap (time between pretreatment HbA1c measurement and start of met-
formin therapy), and treatment group (metformin prescribed as mono-
therapy or dual therapy – metformin added to stable sulfonylurea
treatment), were added as covariates, when available/applicable (Supple-
mentary Table S7 online). In the HOME study, analyses were adjusted
for pretreatment HbA1c, metformin daily dose and creatinine clearance,
and in the SDDS study, pretreatment HbA1c and randomization
group23 were added as covariates.
As the effects of transporter SNPs could depend on metformin level,
or they could be confounded by the effect of other variants, secondary
analyses were performed to explore possible gene-dose and gene-gene
interactions. For gene-dose interactions, we first examined interaction
models that included SNP 3 dose interaction term with dose as a con-
tinuous variable and then dose coded as a dichotomized variable (low or
high dose) in the following model: HbA1c reduction  pre-treatment
HbA1c 1 adherence 1 creatinine clearance 1 baseline gap 1 treatment
group1 dose 1 SNP1 SNP3 dose.
Table 5b Continued
Subgroup SNP
Effect
allele
No. of
studies
No. of
patients Beta SE P value I2 P(Q)
OCTN1 T306I wt/wt OCT2 A270S T 7 1,806 0.081 0.041 0.048 0.0 0.557
MATE1 rs2289669 A 7 1,728 -0.020 0.028 0.469 0.0 0.554
MATE1 rs2252281 C 5 827 -0.001 0.040 0.976 35.2 0.187
MATE2 rs12943590 A 7 1,426 0.018 0.033 0.581 0.0 0.630
OCTN1 T306I v/v OCT2 A270S T 6 634 -0.017 0.067 0.803 31.7 0.198
MATE1 rs2289669 A 7 609 -0.023 0.040 0.571 25.7 0.232
MATE1 rs2252281 C 5 267 0.049 0.122 0.690 63.7 0.027
MATE2 rs12943590 A 7 541 -0.145 0.094 0.121 63.1 0.012
OCTN1 L503F wt/wt OCT2 A270S T 5 1,367 -0.040 0.047 0.394 41.8 0.143
MATE1 rs2289669 A 5 1,274 -0.019 0.031 0.548 0.0 0.724
MATE1 rs2252281 C 4 583 -0.059 0.063 0.344 42.2 0.158
MATE2 rs12943590 A 5 1,114 -0.049 0.057 0.394 53.5 0.072
OCTN1 L503F v/v OCT2 A270S T 5 816 0.106 0.063 0.095 40.2 0.153
MATE1 rs2289669 A 5 768 -0.042 0.045 0.354 0.0 0.982
MATE1 rs2252281 C 4 337 0.017 0.065 0.793 5.6 0.365
MATE2 rs12943590 A 5 584 0.031 0.053 0.561 0.0 0.857
A positive beta is a greater glycemic response to metformin associated with the effect allele.
I2, heterogeneity index; MATE, multidrug and toxin extrusion transporter; OCT1, organic cation transporter 1; P(Q), P value for Cochrane’s Q statistic; SNP,
single-nucleotide polymorphism; v/v, homozygous variant allele carriers; wt/wt, homozygous wild-type allele carriers.
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Next, we assessed the association of SNPs with metformin response
separately for patients taking low (1,000 mg) or high doses (>1,000 mg)
of metformin. The cutoff value of 1,000 mg was chosen based on the median
dose in the largest cohort. The analyses were performed using the same basic
regression model: HbA1c reduction pre-treatment HbA1c1 adherence1
creatinine clearance1 baseline gap1 treatment group1 dose1 SNP.
To examine potential interactions between the variants, additional
exploratory analyses of the effects of individual SNPs were carried out in
the subgroups of individuals who were homozygous for wild-type allele
and of the individuals who were homozygous for variant allele of possibly
confounding SNPs, assuming that impact of the variants could be more
pronounced in more extreme genotype groups. Possible 1 3 1 interac-
tions between SNPs in metformin liver transporters (OCT1 and
MATE1), and SNPs in metformin kidney transporters (OCT2,
MATE1, MATE2-K, and OCTN1) were explored.
All analyses were carried out for the total group of patients treated
with metformin, including monotherapy and dual therapy group (met-
formin added to stable sulfonylurea therapy), and also separately for the
metformin monotherapy group. The results from individual studies were
combined in the meta-analysis using PLINK software under fixed-effects
model (http://pngu.mgh.harvard.edu/purcell/plink/).47 For gene-dose
interaction models, estimates of SNP 3 dose interaction terms were
pooled in the meta-analysis.48 Heterogeneity across studies was assessed
using the Cochran Q test and the I2 heterogeneity index. In case the sub-
stantial heterogeneity was detected (P value for Cochran Q test <0.10),
the results of the random-effects model were presented. Power analyses
were performed using Quanto (http://biostats.usc.edu/Quanto.html).
Forest plots were created using RevMan 5.3 software (Review Manager,
The Nordic Cochrane Centre, The Cochrane Collaboration).
As the primary analysis included nine SNPs and one combined OCT1
genotype, a nominal statistical significance threshold was set to 5 3 1023
(P 5 0.05/10), and a study-wise statistical significance threshold to 2 3
1024 to correct for the overall number of tests performed (P5 0.05/236).
In addition to our main hypothesis, we performed a supplemental,
locus-wise meta-analysis of all common SNPs within the proximity of
the transporter genes to examine the possibility that original associations
reported in previous studies might be driven by other SNPs in these gene
regions. A total of 3,471 variants with minor allele frequency 1% were
tested for association with metformin glycemic response in 6,964 partici-
pants from two MetGen cohorts with available genome-wide association
study imputed data, the GoDARTS and PMT2-EU. The details of geno-
typing, quality control, imputation, association analysis, and meta-
analysis were described in our previous study.49 The experiment-wise
significance threshold for this supplemental analysis was derived from
10,000 permutations of the phenotype in the GoDARTS data,47 which
gave a 95% cutoff for significance of P5 1.63 1024.
Additional Supporting Information may be found in the online version of
this article.
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